Int. J. New. Chem., 2025, Vol. 12, Issue 4, pp. 856-873.

International Journal of New Chemistry
Published online 2025 in http://www.ijnc.ir/.
Open Access

Print ISSN: 2645-7237

Online ISSN: 2383-188x

Review

Innovative Drug Delivery Systems: Nanotechnology in Medicine

Mitra Akbari*

* Eye Research Center, Department of Eye, Amiralmomenin Hospital, School of Medicine, Guilan University of Medical Science, Rasht, Iran

*Corresponding author email: mitra.akbari20@gmail.com

Received: 2025-01-02 *Accepted: 2025-03-05* *Published: 2025-03-06*

ABSTRACT

Nanotechnology has emerged as a transformative force in modern medicine, offering innovative solutions to longstanding challenges in drug delivery. This review explores the advancements and applications of nanotechnology-based drug delivery systems, emphasizing their potential to enhance therapeutic efficacy, minimize side effects, and improve patient outcomes. Key topics include the design and engineering of nanoparticles, liposomes, dendrimers, and polymeric systems that facilitate targeted delivery, controlled release, and increased bioavailability of drugs. The paper also examines the role of nanocarriers in addressing complex medical conditions such as cancer, neurodegenerative diseases, and infectious disorders. Furthermore, it highlights the challenges associated with clinical translation, including biocompatibility, scalability, and regulatory considerations. By synthesizing recent developments and identifying future directions, this review underscores the pivotal role of nanotechnology in revolutionizing drug delivery systems and advancing precision medicine.

Keywords: Nanotechnology, Drug delivery systems, Innovative medicine, Targeted therapy, Biomedical applications.

Introduction

The field of medicine has witnessed transformative advancements over the past century, driven by the relentless pursuit of innovation and the integration of interdisciplinary sciences. Among these, nanotechnology has emerged as a groundbreaking frontier, offering unprecedented opportunities to revolutionize healthcare [1]. The application of nanotechnology in drug delivery systems holds the promise of overcoming some of the most significant challenges in medicine, including drug solubility, bioavailability, targeted delivery, and controlled release. This review paper explores the remarkable potential of these innovative drug delivery systems, focusing on the role of nanotechnology in reshaping the landscape of modern medicine [2]. Drug delivery systems have always been at the heart of therapeutic interventions. The efficacy of a drug is not solely determined by its pharmacological properties but also by its ability to reach the intended site of action in appropriate concentrations while minimizing adverse effects. Traditional drug delivery methods, such as oral tablets, injections, or topical applications, often face limitations such as poor absorption, rapid degradation, or non-specific distribution. These limitations can lead to suboptimal therapeutic outcomes and unintended side effects [3]. The need for more precise and effective delivery mechanisms has spurred significant research into advanced drug delivery systems, with nanotechnology emerging as a key enabler. Nanotechnology, defined as the manipulation and application of materials at the nanoscale (1-100 nanometers), has garnered immense interest across various scientific domains [4]. In medicine, its potential is particularly profound due to its ability to interact with biological systems at the molecular and cellular levels. Nanoparticles, nanocarriers, and other nanostructures offer unique properties such as high surface-area-to-volume ratios, tunable physicochemical characteristics, and the ability to encapsulate therapeutic agents [5]. These features make them ideal candidates for designing innovative drug delivery systems capable of addressing complex medical challenges.

One of the most compelling advantages of nanotechnology-based drug delivery systems is their ability to achieve targeted delivery. Targeted delivery refers to the precise transport of therapeutic agents to specific tissues, cells, or even intracellular compartments while sparing healthy tissues [6]. This approach not only enhances therapeutic efficacy but also reduces systemic toxicity—a critical consideration in the treatment of conditions such as cancer, autoimmune diseases, and infectious diseases [7]. For example, nanoparticles can be engineered to recognize and bind to specific receptors on cancer cells, delivering chemotherapeutic drugs directly to the tumor site while minimizing damage to surrounding healthy tissues [8]. Another significant benefit of nanotechnology in drug delivery is its ability to enable controlled release.

Controlled release systems are designed to release therapeutic agents at a predetermined rate over an extended period, thereby maintaining optimal drug concentrations in the body [9]. This is particularly important for chronic diseases that require long-term treatment regimens. Nanocarriers such as liposomes, dendrimers, and polymeric nanoparticles can be tailored to release drugs in response to specific stimuli, such as pH changes, temperature variations, or enzymatic activity [10]. This level of control not only improves patient compliance but also enhances treatment outcomes. The versatility of nanotechnology-based drug delivery systems extends beyond targeting and controlled release. These systems can also improve the solubility and stability of poorly water-soluble drugs, a common challenge in pharmaceutical development. By encapsulating hydrophobic drugs within nanostructures, researchers can enhance their bioavailability and ensure efficient delivery to the desired site of action [11]. Additionally, nanocarriers can protect sensitive therapeutic agents, such as proteins and nucleic acids, from degradation in the harsh physiological environment, thereby preserving their activity and potency [12]. The integration of nanotechnology into drug delivery systems has also opened new avenues for personalized medicine. Personalized medicine aims to tailor therapeutic interventions to individual patients based on their genetic makeup, lifestyle, and disease characteristics. Nanotechnology enables the development of customizable drug delivery platforms that can be adapted to meet the specific needs of each patient [13]. For instance, nanoparticles can be functionalized with ligands that target biomarkers unique to a patient's disease profile, ensuring highly precise and effective treatment [14]. Despite its immense potential, the application of nanotechnology in drug delivery is not without challenges. Issues such as biocompatibility, toxicity, scalability, and regulatory approval must be carefully addressed to ensure the safe and effective translation of these technologies from the laboratory to clinical practice [15]. Extensive preclinical and clinical studies are required to evaluate the pharmacokinetics, pharmacodynamics, and long-term safety of nanocarrier-based drug delivery systems. Moreover, the cost of developing and manufacturing these advanced systems remains a significant barrier that must be overcome to ensure widespread accessibility [16]. In recent years, numerous nanotechnology-based drug delivery systems have progressed from research laboratories to clinical trials and even commercial applications. Liposomal formulations such as Doxil® (doxorubicin liposome) and Abraxane® (albumin-bound paclitaxel) have demonstrated the clinical feasibility and therapeutic benefits of nanocarrier-based approaches [17]. These success stories underscore the potential of nanotechnology to transform drug delivery paradigms and inspire further innovation in this rapidly evolving field. The implications of nanotechnology-based drug delivery systems extend beyond traditional pharmaceuticals [18]. Emerging areas such as gene therapy, immunotherapy, and regenerative medicine stand to benefit immensely from these advanced delivery platforms. For example, nanoparticles can serve as carriers for gene-editing tools like CRISPR-Cas9 or RNA-based therapeutics such as small interfering RNA (siRNA) and messenger RNA (mRNA). Similarly, nanocarriers can enhance the efficacy of immunotherapeutic agents by facilitating their targeted delivery to immune cells or tumor microenvironments [19]. As we delve deeper into the applications of nanotechnology in medicine, it becomes evident that this interdisciplinary approach holds the key to addressing some of the most pressing healthcare challenges of our time. From combating antibiotic resistance to improving cancer treatment outcomes and enabling precision medicine, the possibilities are vast and transformative [20]. However, realizing this potential requires continued collaboration among scientists, clinicians, engineers, and policymakers. By fostering a multidisciplinary approach and addressing existing challenges, we can unlock the full potential of innovative drug delivery systems powered by nanotechnology [21].

In this review paper, we aim to provide a comprehensive overview of the current state of nanotechnology-based drug delivery systems, highlighting their design principles, applications, advantages, limitations, and future prospects. By examining recent advancements and emerging trends in this field, we hope to shed light on the transformative impact of nanotechnology on modern medicine and inspire further research and innovation in this exciting domain [22].

Liposomes

Liposomes, which are microscopic spherical vesicles formed from lipid bilayers, represent a versatile and highly adaptable platform for drug delivery. These unique structures are composed of amphiphilic molecules that self-assemble into bilayers, creating an internal aqueous core capable of encapsulating hydrophilic drugs while simultaneously incorporating hydrophobic drugs within the lipid bilayer itself [23]. This dual capability allows liposomes to serve as effective carriers for a wide range of pharmaceutical agents. One of their most significant advantages lies in their inherent biocompatibility, which minimizes the risk of adverse immune responses when administered to patients. Additionally, liposomes provide a protective environment for encapsulated drugs, shielding them from enzymatic degradation, hydrolysis, or other destabilizing processes that might occur in the body prior to reaching their intended target. This protective feature enhances drug stability and ensures that a higher proportion of the therapeutic agent remains intact and active upon delivery [24]. Over the years, liposomal drug delivery systems have gained considerable attention and widespread application across various fields of medicine, particularly in oncology. Liposomal formulations have been successfully employed to improve the therapeutic index of anticancer agents by optimizing drug distribution and minimizing off-target effects [25]. A notable example is Doxil® (liposomal doxorubicin), a PEGylated liposomal formulation of the widely used chemotherapeutic agent doxorubicin. This formulation has demonstrated significant clinical benefits, including reduced cardiotoxicity compared to its non-liposomal counterpart, thereby enhancing patient safety and tolerability during treatment [26]. By encapsulating doxorubicin within a liposomal carrier, Doxil® achieves prolonged circulation in the bloodstream and preferential accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect, which is a hallmark of many solid tumors. The field of liposome technology continues to evolve with remarkable innovations aimed at overcoming existing limitations and further optimizing drug delivery performance. One such advancement is the development of PEGylated liposomes, which are modified by attaching polyethylene glycol (PEG) chains to their surface [27]. This modification imparts a "stealth" property to liposomes, reducing recognition and clearance by the mononuclear phagocyte system (MPS). As a result, PEGylated liposomes exhibit extended circulation times in the bloodstream, allowing for improved bioavailability and enhanced therapeutic efficacy. Another exciting area of research involves stimuli-responsive or "smart" liposomes, which are engineered to release their payload in response to specific environmental triggers such as pH changes, temperature fluctuations, or enzymatic activity [28]. These stimuli-responsive systems enable controlled and site-specific drug release, thereby minimizing systemic side effects and maximizing therapeutic outcomes. In addition to their applications in cancer therapy, liposomes are being explored for the delivery of a wide array of other therapeutic agents, including antibiotics, antifungals, vaccines, and gene therapies. Their ability to encapsulate diverse types of molecules makes them an attractive platform for addressing unmet medical needs across a broad spectrum of diseases [29]. Furthermore, ongoing research aims to refine liposome design by incorporating targeting ligands such as antibodies, peptides, or small molecules onto their surface. These targeted liposomes hold great promise for achieving precise delivery to specific cells or tissues, further enhancing efficacy while reducing off-target effects [30]. The versatility, biocompatibility, and adaptability of liposomes underscore their immense potential as a cornerstone of modern drug delivery systems. As advancements in nanotechnology and materials science continue to drive innovation in this field, it is likely that liposomal formulations will play an increasingly prominent role in revolutionizing therapeutic approaches and improving patient outcomes across a wide range of medical disciplines.

Polymeric Nanoparticles

Polymeric nanoparticles represent a groundbreaking advancement in the field of nanomedicine and drug delivery systems. These microscopic particles are meticulously engineered using biodegradable polymers, such as polylactic acid (PLA), polyglycolic acid (PGA), or their copolymer, poly(lactic-co-glycolic acid) (PLGA). The choice of these polymers is particularly advantageous due to their biocompatibility, safety profile, and ability to degrade into non-toxic byproducts that can be naturally eliminated from the body. Polymeric nanoparticles are uniquely designed to encapsulate therapeutic agents, including drugs, within their polymeric matrix or to adsorb these agents onto their surface, depending on the desired application [31]. This dual capability allows for remarkable versatility in drug delivery strategies. One of the most significant advantages of polymeric nanoparticles is their ability to provide sustained and controlled drug release over extended periods. This feature can minimize the need for frequent dosing, improve patient compliance, and maintain therapeutic drug levels in the body for optimal efficacy. Additionally, their high drug-loading capacity ensures that a substantial amount of the therapeutic agent can be delivered in a single dose, reducing the overall volume of administration. The surface properties of polymeric nanoparticles can also be tailored to achieve specific objectives, such as enhanced targeting of diseased tissues, improved stability in biological environments, or reduced immune recognition [32]. These tunable surface characteristics are achieved through modifications like attaching ligands, antibodies, or polyethylene glycol (PEG) molecules to the nanoparticle surface. Polymeric nanoparticles have demonstrated immense potential in addressing a wide range of medical challenges and have been extensively utilized in the treatment of various diseases. In oncology, they have been employed to deliver chemotherapeutic agents directly to tumor sites, minimizing systemic toxicity and improving therapeutic outcomes. In diabetes management, polymeric nanoparticles have been explored for the sustained delivery of insulin or other antidiabetic drugs, providing better glycemic control [33]. They have also shown promise in combating infectious diseases by delivering antimicrobial agents more effectively to target sites, overcoming issues like drug resistance and poor bioavailability. Beyond these applications, researchers are continuously exploring the use of polymeric nanoparticles in areas such as gene therapy, vaccine delivery, and regenerative medicine. Their ability to protect sensitive biomolecules like DNA, RNA, or proteins from degradation and deliver them precisely to target cells has opened new avenues for treating genetic disorders and developing next-generation vaccines. Overall, polymeric nanoparticles are a versatile and powerful tool in modern medicine, with the potential to revolutionize how diseases are treated and managed.

Dendrimers

Dendrimers, a fascinating and highly versatile class of macromolecules, are characterized by their unique, highly branched, tree-like architecture. These nanoscale structures possess a meticulously defined molecular framework that gives rise to a symmetrical and uniform shape, with layers of branching units radiating outward from a central core. What sets dendrimers apart from other polymers is the presence of multiple functional groups densely packed on their surface. These functional groups, which can be chemically tailored with great precision, provide an extraordinary platform for attaching a wide variety of molecules, including therapeutic agents, diagnostic tools, and targeting ligands [34]. This adaptability has positioned dendrimers as a promising tool in the field of nanomedicine and beyond. One of the most exciting applications of dendrimers lies in drug delivery systems, where their unique structural properties enable them to overcome many of the challenges associated with conventional delivery methods. The ability to conjugate or encapsulate drugs within the dendrimer's core or attach them to its surface allows for the efficient transport of therapeutic agents to specific sites in the body [35]. For instance, by attaching targeting ligands to the surface of dendrimers, scientists can direct these nanocarriers to recognize and bind to specific receptors on diseased cells, such as cancer cells. This targeted approach minimizes off-target effects and enhances the therapeutic efficacy of anticancer drugs. Furthermore, dendrimers' nanoscale size and uniform shape ensure that they can circulate through the bloodstream and penetrate tissues more effectively than larger or irregularly shaped particles.

Another remarkable feature of dendrimers is their ability to control drug release kinetics with exceptional precision. By modifying the chemical composition of their core or surface functional groups, researchers can design dendrimers that release their payloads at a desired rate or in response to specific stimuli, such as changes in pH, temperature, or enzymatic activity. This level of control is particularly advantageous for treating diseases like cancer, where localized and sustained drug release can significantly improve therapeutic outcomes while reducing systemic toxicity. Additionally, dendrimers' well-defined structure and monodispersity contribute to their predictable biodistribution and pharmacokinetics, ensuring that they behave consistently within biological systems. Beyond drug delivery, dendrimers hold immense potential in other areas of healthcare and biotechnology [36]. For example, they have been explored as carriers for gene therapies, where they can facilitate the safe and efficient delivery of genetic material, such as DNA or RNA, into cells. Their positively charged surface groups allow them to complex with negatively charged nucleic acids, protecting these delicate molecules from degradation and enhancing their cellular uptake. Similarly, dendrimers have shown promise in antimicrobial applications by disrupting bacterial membranes or delivering antibiotics directly to infection sites. Moreover, dendrimers are being investigated for their role in medical imaging and diagnostics. By conjugating imaging agents, such as fluorescent dyes or contrast agents for MRI and CT scans, to their surface, dendrimers can serve as highly effective imaging probes [37]. Their ability to accumulate at specific sites within the body enhances the sensitivity and accuracy of diagnostic techniques, enabling earlier detection and better monitoring of diseases. In summary, dendrimers represent a groundbreaking advancement in the field of nanotechnology due to their highly branched structure, customizable surface functionality, and unique physicochemical properties. Their versatility has opened up a wide range of applications in drug delivery, gene therapy, antimicrobial treatments, and medical imaging. By enabling precise control over drug release kinetics, biodistribution, and targeting capabilities, dendrimers have demonstrated tremendous potential to transform modern medicine and improve patient outcomes. As research continues to uncover new possibilities for these remarkable macromolecules, it is clear that dendrimers are poised to play a pivotal role in shaping the future of healthcare and biotechnology.

Solid Lipid Nanoparticles (SLNs)

Solid Lipid Nanoparticles (SLNs) are an innovative and versatile class of nanocarriers that have garnered significant attention in the field of drug delivery and biomedical research due to their unique structural and functional attributes [38]. These nanoparticles are primarily composed of lipids that remain solid at both room temperature and body temperature, which are stabilized by the inclusion of surfactants to prevent particle aggregation and ensure stability during storage and application. The solid lipid matrix serves as a robust and biocompatible platform for encapsulating therapeutic agents, offering a promising alternative to traditional delivery systems. SLNs effectively combine the beneficial properties of liposomes, which are lipid-based vesicles, and polymeric nanoparticles, which are synthesized from biodegradable polymers. By doing so, they address some of the critical challenges associated with these conventional systems. For instance, SLNs circumvent the issue of burst release often observed in polymeric nanoparticles, where a large amount of the drug is released prematurely, potentially leading to suboptimal therapeutic outcomes or adverse effects [39]. Additionally, they eliminate concerns related to polymer toxicity, which can arise from the degradation products of certain polymers used in drug delivery systems. One of the most remarkable features of SLNs is their ability to improve the bioavailability of poorly water-soluble drugs, which represent a significant proportion of pharmaceutical compounds. By encapsulating such drugs within their lipid matrix, SLNs enhance their solubility, stability, and controlled release properties, thereby optimizing their therapeutic efficacy [40]. This capability makes SLNs particularly suitable for addressing the challenges associated with hydrophobic drugs that are otherwise difficult to formulate using conventional delivery methods. Furthermore, SLNs have been extensively investigated for their potential applications in a wide range of medical fields. In the realm of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease, SLNs have been explored as a means to deliver drugs across the blood-brain barrier, a highly selective barrier that often limits the effectiveness of conventional therapies. Their small size, lipid composition, and surface modifications allow SLNs to interact with specific transport mechanisms and enhance drug delivery to the brain. In addition to their applications in neurology, SLNs have shown promise in the treatment of cardiovascular disorders. These nanoparticles can be designed to deliver cardiovascular drugs in a targeted and controlled manner, potentially reducing side effects and improving patient outcomes. For example, SLNs can be engineered to release drugs in response to specific physiological stimuli or over an extended period, ensuring sustained therapeutic effects. Moreover, in the field of dermatology, SLNs have been utilized for topical drug delivery due to their ability to penetrate the skin barrier effectively. They offer advantages such as improved drug stability, reduced skin irritation, and enhanced penetration into deeper layers of the skin, making them suitable for treating various dermatological conditions, including psoriasis, acne, and skin infections. The versatility of SLNs extends beyond their role as drug carriers [41]. They can also be employed for diagnostic purposes and as carriers for imaging agents in medical imaging applications. Their biocompatibility and ability to encapsulate a wide range of substances make them an attractive option for developing multifunctional systems that combine therapeutic and diagnostic capabilities, often referred to as theranostics. Additionally, SLNs are amenable to large-scale production using cost-effective and environmentally friendly methods, which further enhances their appeal for pharmaceutical and clinical applications. In summary, Solid Lipid Nanoparticles represent a cutting-edge platform that bridges the gap between traditional and modern drug delivery systems by leveraging their unique structural properties and functional versatility. Their ability to enhance the solubility and bioavailability of poorly water-soluble drugs, coupled with their biocompatibility and controlled release characteristics, makes them a valuable tool for addressing complex medical challenges. With ongoing research and advancements in nanotechnology, SLNs hold immense potential for revolutionizing the treatment of various diseases and improving patient care across multiple therapeutic areas.

Inorganic Nanoparticles

Inorganic nanoparticles, including but not limited to gold nanoparticles, quantum dots, and mesoporous silica nanoparticles, represent a fascinating and rapidly advancing area of nanotechnology that has garnered significant attention from researchers and medical professionals alike. These nanoparticles possess a diverse range of unique optical, magnetic, and structural properties that make them highly versatile and valuable for numerous applications in both therapeutic and diagnostic fields. Gold nanoparticles, for instance, are particularly renowned for their remarkable optical properties, which can be harnessed for various biomedical purposes. One of their most notable applications is in photothermal therapy for cancer treatment, where their ability to absorb light and convert it into heat is utilized to selectively destroy cancerous cells while minimizing damage to surrounding healthy tissues. This innovative approach has opened up new possibilities in minimally invasive cancer treatments. Quantum dots, another type of inorganic nanoparticle, are celebrated for their exceptional fluorescence properties, which make them ideal for imaging applications. Their ability to emit bright and stable light across a wide spectrum of wavelengths has enabled advancements in cellular imaging, molecular tracking, and even the development of highly sensitive diagnostic assays. Meanwhile, mesoporous silica nanoparticles stand out due to their unique structural characteristics, such as a high surface area, tunable pore size, and excellent biocompatibility. These features make them an excellent platform for targeted drug delivery systems. By loading therapeutic agents into their porous structure, mesoporous silica nanoparticles can deliver drugs with high precision to specific tissues or cells, thereby enhancing treatment efficacy while reducing systemic side effects. Moreover, the versatility of these inorganic nanoparticles extends beyond the examples mentioned above. Researchers have been exploring their potential in areas such as biosensing, gene delivery, and even vaccine development. For instance, gold nanoparticles have been incorporated into biosensors to detect biomarkers with high sensitivity and specificity. Similarly, mesoporous silica nanoparticles are being investigated as carriers for gene therapies, where their ability to protect genetic material from degradation and facilitate its delivery into target cells holds promise for treating genetic disorders. The adaptability of these nanoparticles also allows for surface functionalization, enabling them to be tailored for specific applications by attaching various ligands, antibodies, or other molecules to their surfaces. In summary, the field of inorganic nanoparticles is a dynamic and multidisciplinary area of research that continues to push the boundaries of what is possible in medicine and biotechnology. From cancer therapy and drug delivery to imaging and diagnostics, the unique properties of nanoparticles such as gold nanoparticles, quantum dots, and mesoporous silica nanoparticles have the potential to revolutionize healthcare by providing innovative solutions to some of the most challenging medical problems. As research in this field progresses, it is likely that these tiny yet powerful materials will play an increasingly prominent role in shaping the future of medicine.

Applications of Nanotechnology-Based Drug Delivery Systems

The versatility of nanotechnology-based drug delivery systems has enabled their application across a wide range of medical fields. Below are some notable examples:

Cancer Therapy

Cancer remains one of the most impactful and exciting fields where nanotechnology is reshaping modern medicine. This cutting-edge approach is paving the way for groundbreaking innovations in diagnosis, treatment, and patient care, presenting opportunities that could revolutionize oncology. Central to these advancements is the development of nanoparticles—remarkably adaptable tools crafted to deliver therapeutic drugs directly to tumor cells with unparalleled precision. This targeted approach significantly reduces damage to nearby healthy tissues while minimizing the side effects often associated with traditional cancer therapies, such as chemotherapy. The precision of nanoparticles hinges on the functionalization of their surfaces with specific targeting agents, including antibodies, peptides, or small molecules. These agents are intricately designed to recognize unique molecular markers expressed primarily on the surfaces of tumor cells, markers that are either absent or minimally found on healthy cells. This strategic interaction ensures an extraordinary level of specificity, allowing nanoparticles to target cancerous cells while sparing normal tissues from collateral damage. Moreover, nanoparticles have shown profound versatility in enhancing cancer treatment effectiveness, particularly in addressing multidrug resistance (MDR)—a formidable obstacle in oncology. MDR occurs when cancer cells adapt to block or neutralize the therapeutic impact of drugs, diminishing their potency over time. Leveraging nanoparticles uncovers a dual strategy to combat this resistance. For one, they bypass cancer cells' efflux pumps, specialized proteins designed to eject chemotherapeutic agents, by delivering therapeutic compounds directly inside the cells, often within the cytoplasm or nucleus. Second, nanoparticles serve as carriers for gene-silencing agents, such as small interfering RNAs (siRNAs) or antisense oligonucleotides, which can inhibit the production of resistance-inducing proteins on a genetic level. This dual functionality not only boosts the efficacy of existing drug regimens but lays the groundwork for more resilient treatment protocols. The adaptability of nanoparticles does not stop at therapeutic drug delivery or overcoming MDR. Another revolutionary feature is their integration of therapy and diagnostics into a single "theranostic" platform. These engineered nanoparticles combine imaging agents and drugs, allowing real-time tracking of a treatment's delivery and efficacy within the patient's body. This fusion gives clinicians vital information to tailor treatments to suit individual patient responses. Additionally, nanoparticles can be designed to react to environmental cues within the tumor, such as shifts in pH levels, enzyme activities, or temperature changes. These stimuli-responsive systems ensure drugs are released precisely at the desired site and time, furthering their specificity and reducing unintended consequences. In essence, the rise of nanotechnology in cancer treatment heralds a transformative era in oncology. From precision-targeted therapies to overcoming drug resistance and integrating diagnostics with therapeutic interventions, nanoparticles offer solutions to persistent challenges in cancer care. As research continues its rapid progression, the promise of nanoparticles in improving treatment outcomes with reduced side effects grows ever stronger, presenting an optimistic future for patients and medical professionals striving against this complex disease.

Neurological Disorders

Neurological disorders represent a significant and growing concern in the realm of medical science, as they often involve complex and multifaceted challenges in both diagnosis and treatment. One of the most formidable obstacles in treating these disorders is the blood-brain barrier (BBB), a highly selective and protective layer that shields the central nervous system (CNS) from potentially harmful substances circulating in the bloodstream. While this barrier serves an essential physiological function, it also limits the ability of therapeutic agents to reach the brain, thereby complicating efforts to address conditions such as Alzheimer's disease, Parkinson's disease, and glioblastoma. However, recent advances in nanotechnology have opened up new possibilities for overcoming this challenge. Nanoparticles, which are tiny particles ranging in size from 1 to 100 nanometers, have emerged as a promising tool for delivering drugs across the BBB. These nanoparticles can be engineered to exploit specific mechanisms, such as receptor-mediated transport, adsorptive-mediated transport, or transient disruption of the BBB, to facilitate their passage into the CNS. One of the most exciting aspects of nanoparticle-based drug delivery is the ability to tailor their composition, size, surface charge, and functionalization to optimize their interaction with the BBB and target specific brain regions. For example, lipid-based nanoparticles, including liposomes and solid lipid nanoparticles, have demonstrated considerable potential in delivering therapeutic agents to the brain. These nanoparticles can encapsulate both hydrophilic and hydrophobic drugs, protecting them from degradation and enhancing their bioavailability. In the context of Alzheimer's disease, lipid-based nanoparticles have been employed to deliver anti-inflammatory drugs aimed at reducing neuroinflammation, a hallmark of the disease that contributes to neuronal damage and cognitive decline. By targeting inflammatory pathways, these nanoparticles not only help alleviate symptoms but may also slow disease progression. Similarly, in Parkinson's disease, which is characterized by the degeneration of dopaminergic neurons in the substantia nigra, nanoparticles have been explored as carriers for neuroprotective agents and dopamine precursors. These nanoparticles can be designed to release their payloads in a controlled manner, ensuring sustained therapeutic effects while minimizing systemic side effects. Moreover, surface modifications of nanoparticles with ligands such as transferrin or lactoferrin can enhance their ability to cross the BBB via receptor-mediated endocytosis, further improving their efficacy. Glioblastoma, an aggressive form of brain cancer with a poor prognosis, presents another area where nanoparticles have shown promise. Traditional chemotherapy for glioblastoma is often hindered by the BBB, as well as by the tumor's heterogeneity and resistance to treatment. Nanoparticles can address these challenges by delivering chemotherapeutic agents directly to the tumor site, increasing drug concentration within the tumor while reducing off-target effects. Additionally, nanoparticles can be loaded with multiple therapeutic agents or combined with imaging agents for theranostic applications, enabling simultaneous treatment and monitoring of the disease. Beyond their role in drug delivery, nanoparticles hold potential for diagnostic applications in neurological disorders. For instance, they can be functionalized with contrast agents for imaging techniques such as magnetic resonance imaging (MRI) or positron emission tomography (PET), aiding in early detection and monitoring of disease progression. Furthermore, advancements in nanotechnology continue to drive innovation in this field, with researchers exploring novel materials such as polymeric nanoparticles, dendrimers, and quantum dots for CNS applications. In conclusion, while the blood-brain barrier poses a significant challenge in the treatment of neurological disorders, nanotechnology offers a promising avenue for overcoming this obstacle. By enabling targeted and efficient drug delivery to the central nervous system, nanoparticles have the potential to revolutionize the management of diseases such as Alzheimer's disease, Parkinson's disease, and glioblastoma. As research in this field progresses, it is hoped that these advancements will translate into improved outcomes and quality of life for patients suffering from these debilitating conditions.

Infectious Diseases

The emergence of antibiotic resistance has necessitated the development of alternative therapeutic strategies. Nanoparticles can enhance the efficacy of existing antibiotics by improving their pharmacokinetics and targeting capabilities. They can also serve as carriers for antimicrobial peptides or nucleic acids that target bacterial genes. Furthermore, nanotechnology has been employed in vaccine development, with nanoparticle-based vaccines showing promise in eliciting robust immune responses.

Cardiovascular Diseases

Nanoparticles have been explored for delivering drugs to treat cardiovascular diseases such as atherosclerosis, myocardial infarction, and hypertension. For example, lipid nanoparticles loaded with anti-inflammatory agents can target atherosclerotic plaques to reduce inflammation and prevent plaque rupture. Similarly, polymeric nanoparticles have been used to deliver angiogenic factors to promote vascular regeneration after myocardial infarction.

Gene Therapy

Gene therapy involves delivering genetic material to cells to treat or prevent diseases caused by genetic mutations. Nanoparticles provide a non-viral alternative for gene delivery, offering advantages such as reduced immunogenicity and the ability to carry large genetic payloads. Cationic liposomes and polymeric nanoparticles have been used to deliver DNA or RNA molecules for treating genetic disorders, cancer, and viral infections.

Conclusions and Future Perspectives

In conclusion, nanotechnology-based drug delivery systems have emerged as a transformative approach in modern medicine, offering unprecedented precision, efficiency, and versatility in addressing complex therapeutic challenges. These innovative systems enable targeted delivery, controlled release, and enhanced bioavailability of drugs, significantly improving treatment outcomes while minimizing adverse effects. Advances in nanocarriers, including liposomes, dendrimers, polymeric nanoparticles, and inorganic nanoparticles, have demonstrated immense potential across a wide range of medical applications, from cancer therapy and infectious diseases to regenerative medicine and personalized treatments. Despite these promising developments, several challenges remain, including scalability of production, regulatory hurdles, potential toxicity, and long-term stability. Future perspectives in this field should focus on overcoming these limitations by fostering interdisciplinary collaborations, advancing nanomaterial design, and integrating artificial intelligence and machine learning to optimize drug delivery strategies. Furthermore, clinical translation requires robust preclinical studies and standardized protocols to ensure safety and efficacy. With continued innovation and investment, nanotechnology holds the promise of revolutionizing the landscape of drug delivery and paving the way for more effective and patient-centric medical solutions.

References

1. B. Sahiner, A. Pezeshk, L. M. Hadjiiski, et al., Med. Phys. **46**, 1 (2019).
2. M. S. O. Pijeira, H. Viltres, J. Kozempel, et al., EJNMMI Radiopharm. Chem. **7**, 8 (2022).
3. M. A. Westcott, D. M. Coldwell, D. M. Liu, et al., Adv. Radiat. Oncol. **1**, 351 (2016).
4. I. M. Ariel and G. T. Pack, Thoraxchir. Vask. Chir. **14**, 286 (1966).
5. N. Simon, R. Siffert, M. G. Baron, et al., Cancer **21**, 453 (1968).
6. H. L. Volchok and J. L. Kulp, Phys. Rev. **97**, 102 (1955).
7. A. Saini, A. Wallace, S. Alzubaidi, et al., J. Clin. Med. **8**, 55 (2019).
8. B. Gray, US Patent No. 11743530 (P.A.P., 2007), No. 11, p. 6.
9. G. J. Ehrhardt and D. E. Day, Int. J. Radiat. Appl. Instrum., Part B **14**, 233 (1987).
10. S. Harada, S. Ehara, K. Ishii, et al., Int. J. Radiat. Oncol. Biol. Phys. **75**, 455 (2009).
11. F. Madani, S. S. Esnaashari, T. J. Webster, et al., J. Control. Release **349**, 649 (2022).

12. E. Blanco, H. Shen, and M. Ferrari, Nat. Biotechnol. **33**, 941 (2015).

13. F. Yugui, H. Wang, D. Sun, et al., Biomed. Pharmacother. **114**, 108820 (2019).

14. T. Tadros, P. Izquierdo, J. Esquena, et al., Adv. Colloid Interface Sci. **108**, 303 (2004).

15. M. Fraga, R. S. Schuh, É. Poletto, et al., Curr. Gene Ther. **21**, 464 (2021).

16. J. B. Đoković, S. Demisli, S. Savić, et al., Pharm. **14**, 1666 (2022).

17. S. N. Harun, S. A. Nordin, S. S. A. Gani, et al., Int. J. Nanomed., 2571 (2018).

18. G. Ahmad, R. El Sadda, G. Botchkina, et al., Cancer Lett. **406**, 71 (2017).

19. A. B. Mirgorodskaya, M. Y. Koroleva, R. A. Kushnazarova, et al., Nanotechnology **33**, 155103 (2022).

20. S. Jagdale, M. Narwade, A. Sheikh, et al., Int. J. Pharm. **637**, 122894 (2023).

21. S. Aly, A. H. El-Kamel, E. Sheta, et al., Int. J. Pharm. **637**, 123163 (2023).

22. A. Shirvani, S. A. H. Goli, J. Varshosaz, et al., J. Dispers. Sci. Technol. **44**, 1809 (2023).

23. A. Khosa, S. Reddi, and R. N. Saha, Biomed. Pharmacother. **103**, 598 (2018).

24. W. I. Higuchi and J. Misra, J. Pharm. Sci. **51**, 459 (1962).

25. M. Y. Koroleva and E. V. Yurtov, Russ. Chem. Rev. **90**, 293 (2021).

26. D. J. McClements and S. M. Jafari, in *Nanoemulsions: Formulation, Applications, and Characterization* (Academic, New York, 2018), Chap. 1, p. 3.

27. M. Y. Koroleva and E. V. Yurtov, Russ. Chem. Rev. **81**, 21 (2012).

28. M. Koroleva, I. Portnaya, E. Mischenko, et al., J. Colloid Interface Sci. **610**, 61 (2022).

29. M. Koroleva, Phys. Chem. Chem. Phys. **25**, 21836 (2023).

30. S. M. Alshahrani, J. Drug Deliv. Sci. Technol. **68**, 103085 (2022).

31. H. A. Joshi, R. S. Patwardhan, D. Sharma, et al., Int. J. Pharm. **595**, 120181 (2021).

32. M. Adhikari and R. Arora, Mutat. Res. Genet. Toxicol. Environ. Mutagen. **792**, 1 (2015).
33. J. Youshia, A. O. Kamel, and A. El Shamy, Eur. J. Pharm. Sci. **163**, 105887 (2021).
34. D. S. Patil, K. Prabhakaran, C. Durgaprasad, et al., Ceram. Int. **35**, 515 (2009).
35. P. Izquierdo, J. Feng, J. Esquena, et al., J. Colloid Interface Sci. **285**, 388 (2005).
36. M. Y. Koroleva, T. Y. Nagovitsina, and E. V. Yurtov, Mendeleev Commun. **25**, 389 (2015).
37. T. V. Zotova, V. V. Arslanov, and I. A. Gagina, Thin Solid Films **326**, 223 (1998).
38. A. D. Shirokikh, V. A. Anikina, E. A. Zamyatina, et al., Nanosyst.: Phys. Chem. Math. **14**, 89 (2023).
39. M. Y. Koroleva and E. V. Yurtov, Russ. Chem. Rev. **91**, RCR5024 (2022).
40. R. Hickey, M. F. Mulcahy, R. J. Lewandowski, et al., Int. J. Radiat. Oncol. Biol. Phys. **88**, 1025 (2014).
41. ISO 11137-2:2013: Sterilization of health care products - Radiation - Part 2: Establishing the sterilization dose.

HOW TO CITE THIS ARTICLE

Mitra Akbari, “**Innovative Drug Delivery Systems: Nanotechnology in Medicine**” International Journal of New Chemistry., 2025; 12(4), 856-873.